Stocks Health care MYGN
NASDAQ · Health careMyriad Genetics Inc (MYGN)
Myriad Genetics Inc brought in $806.6M of revenue over the twelve months to June 30, 2026, down 3.2% from a year earlier. It posted a net loss of $112.6M. At June 30, 2026 it held $115.2M in cash against $120.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.
What Myriad Genetics Inc does
Myriad Genetics Inc is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker MYGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $824.5M | -$365.9M | -$3.95 | n/a |
| 2024 | $837.6M | -$127.3M | -$1.41 | n/a |
| 2023 | $753.2M | -$263.3M | -$3.18 | n/a |
| 2022 | $678.4M | -$112M | -$1.39 | -$151.6M |
| 2021 | $690.6M | -$27.2M | -$0.35 | $600K |
| 2020 | $557.1M | -$223.6M | -$2.99 | n/a |
Latest SEC filings
What Myriad Genetics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026
- September 4, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- July 31, 2026Quarterly report 10-Q · period to June 30, 2026
- July 30, 2026
- June 23, 2026
- June 4, 2026
- June 4, 2026
Questions about MYGN
What does Myriad Genetics Inc do?
Myriad Genetics Inc is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker MYGN.
Is Myriad Genetics Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $112.6M on revenue of $806.6M.
How much revenue does Myriad Genetics Inc make?
Over the twelve months to June 30, 2026 Myriad Genetics Inc reported revenue of $806.6M. That is 3.2% less than a year earlier.
When did Myriad Genetics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 22, 2026.
Similar companies
Follow MYGN
Get an email when Myriad Genetics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Follow MYGN: get an email when it filesWhere the numbers come from
Financial figures are the values Myriad Genetics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.